Upadacitinib for the treatment of rheumatoid arthritis.

Authors: Serhal L, Edwards CJ Abstract INTRODUCTION: Tofacitinib and baricitinib have recently been approved as second-line treatments for RA though their maximum expected efficacy may be limited by dose-related toxicities. Upadacitinib selectively inhibits JAK1 which could potentially reduce JAK2 and JAK3-related side effects. Areas covered: In this paper, we review a newly developed oral selective Janus kinase inhibitor (Jakinib), upadacitinib for the treatment of Rheumatoid arthritis (RA). The doses of upadacitinib extended-release 15 and 30 mg daily selected in phase III RA studies have shown a near-maximum efficacy in phase II studies. Upadacitinib inhibited radiographic progression and displayed rapid and sustained clinical and functional efficacy when in combination with met...

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2qyCYnL